Immatics' Phase 3 melanoma cell therapy trial heads toward 2026 readout
SUPRAME is the only Phase 3 trial testing a PRAME-targeted cell therapy in previously treated cutaneous melanoma, with a pre-specified analysis due in 2026 while the trial still recruits toward 360 patients.
Executive Summary
- Immatics is running the only Phase 3 trial in the world testing a PRAME-directed cell therapy against standard second-line treatment in cutaneous melanoma, and the sponsor has reiterated that a pre-specified data analysis is due sometime in 2026.
- The trial is a randomized, controlled comparison, not a single-arm study, so unlike most of the therapy's prior evidence, this readout can support a claim of superiority over investigator's choice of treatment rather than just tumor-shrinkage in an uncontrolled cohort.
- The trial is still actively recruiting toward its enrollment target, with no protocol instability or endpoint changes recorded, which means execution is not currently the open question heading into the analysis window.
- The sponsor's 2026 guidance for the analysis sits ahead of the trial's own registered primary completion date in the registry, a gap that has not been reconciled and bears watching as the year progresses.
- Because no other Phase 3 program shares this mechanism-indication pairing, the result will be read as evidence for or against the entire PRAME-targeted cell therapy approach, not just this one drug.
The catalyst
Immatics N.V. told investors on May 12, 2026 that its Phase 3 SUPRAME trial of anzu-cel, formerly called IMA203, is expected to trigger a pre-specified interim and final analysis in 2026, part of the company's push toward what it calls its first commercial launch in 2027. Chief Executive Harpreet Singh described the company as "entering a pivotal period as we continue to progress toward the pre-specified interim and final analyses from the Phase 3 SUPRAME trial of anzu-cel and actively prepare for commercialization in 2027". The trial, registered as NCT06743126, randomizes previously treated patients with unresectable or metastatic cutaneous melanoma to anzu-cel or investigator's choice of treatment, with progression-free survival assessed by blinded independent central review as the primary endpoint. Immatics+1Immatics Announces First Quarter 2026 Financial Results and Business UpdateMay 12, 2026SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaNCT06743126
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial design and status
SUPRAME enrolls HLA-A*02:01-positive patients with ECOG performance status 0 or 1 who have progressed on at least one PD-1 inhibitor, targeting 360 patients across sites in the United States, Germany, the United Kingdom, France, the Netherlands and Canada. The trial remains in Recruiting status, having started on January 14, 2025, and carries nine secondary endpoints including objective response rate, overall survival and treatment-emergent adverse events alongside the primary progression-free survival measure. Enrollment has held flat at its 360-patient anticipated target with no growth or contraction recorded, and the protocol carries a Stable stability label with no primary-endpoint amendments and no post-completion outcome changes. NCT06743126SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaNCT06743126
The timing gap
The registry lists a primary completion date of January 1, 2028, which sits outside the sponsor's stated 2026 window for triggering the interim and final analyses. Immatics carried the same 2026 guidance forward from its full-year 2025 update into its first-quarter 2026 release, repeating the expectation without narrowing the timing further. The company's regulatory roadmap assumes a Biologics License Application submission in the first half of 2027 built on the SUPRAME data, which depends on the 2026 analysis landing as guided. NCT06743126+1SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaNCT06743126Immatics Announces First Quarter 2026 Financial Results and Business UpdateMay 12, 2026
The competitive frame
SUPRAME is the only industry-sponsored Phase 3 trial for the PRAME target in previously treated advanced cutaneous melanoma; other PRAME-directed programs remain in Phase 1 or Phase 2, including Immunocore's brenetafusp, a PRAME-targeted bispecific now in a separate Phase 3 trial in first-line, treatment-naive melanoma rather than this previously treated population. No competitor shares both the PRAME target and Phase 3 stage in this specific line of therapy, leaving SUPRAME without a resolved same-class precedent to benchmark its progression-free survival result against. The nearest modality neighbors are earlier-stage cell therapies such as lifileucel and tumor-infiltrating lymphocyte programs in melanoma, which test different antigens and do not bear directly on PRAME biology.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.